Investment analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a report issued on Saturday. The firm set a "sell" rating on the stock.
A number of other research analysts have also weighed in on VNRX. Benchmark reissued a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reiterated a "buy" rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Thursday.
Get Our Latest Stock Report on VolitionRx
Shares of NYSE:VNRX opened at $0.60 on Friday. The stock has a market cap of $55.60 million, a PE ratio of -1.67 and a beta of 1.20. The stock's fifty day simple moving average is $0.62 and its two-hundred day simple moving average is $0.65. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.22.
In related news, Director Guy Archibald Innes purchased 174,764 shares of the firm's stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 358,266 shares of company stock valued at $204,212 in the last ninety days. 12.80% of the stock is currently owned by insiders.
An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC raised its holdings in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 15.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 730,448 shares of the company's stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.09% of the company's stock.
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.